AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.

AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?

The post AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? appeared first on 24/7 Wall St.. Every drugmaker eventually loses its biggest product to generics or biosimilars. For an income investor, the question is whether newer drugs bring in enough cash to cover the…